Core Viewpoint - The successful IPO of Shenzhen Beixin Life Technology Co., Ltd. marks the second company to pass the review under the newly restarted fifth set of standards for the Sci-Tech Innovation Board [1] Company Overview - Beixin Life focuses on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, aiming to revolutionize solutions in this field [3] - The company is recognized as a national high-tech enterprise and has developed China's first domestically innovative 60MHz high-definition IVUS product approved by the National Medical Products Administration [3][4] - Beixin Life is the first domestic medical device company to offer a combination of FFR and IVUS products, addressing the previously import-dependent market for coronary artery disease diagnosis in China [3][4] Product Development - Since its establishment, Beixin Life has launched 11 products and has 6 products under development, covering five major categories: IVUS systems, FFR systems, vascular access products, shockwave balloon therapy systems, and electrophysiological solutions [4][5] - The core IVUS system is noted for its high-definition, high-speed, and intelligent features, which facilitate precise PCI strategy formulation [4] - The FFR system is recognized as the gold standard for PCI treatment guidance and has received high-level recommendations from various domestic and international guidelines [4] Financial Performance - From 2022 to 2024, Beixin Life's projected revenues are 92.45 million yuan, 184 million yuan, and 317 million yuan, with net profits of -179 million yuan, -164 million yuan, and -6.29 million yuan respectively [5] - The company plans to raise 952 million yuan through its IPO to fund the construction of an interventional medical device industrialization base, R&D projects, and to supplement working capital [5] - Cumulatively, the company has invested over 389 million yuan in R&D from 2022 to 2024, accounting for over 65% of its total revenue during this period [5]

在国家高性能医疗器械创新中心发布的2024年度医疗器械行业创新生态洞察评估中，北芯生命凭借科技 创新实力和出海成果，成功入选"2024年医疗器械行业新锐企业100强创新指数"榜单以及"2024年医疗器 械行业海外拓展卓越企业"榜单。这不仅是对北芯生命过往努力的认可，也预示着其在未来行业发展中 具备巨大潜力。 未来，北芯生命将继续以"成为有长久影响力的世界级医疗科技企业"为愿景，持续投入研发，为全球心 血管疾病患者带来更多优质的诊疗选择，推动心血管精准介入领域不断向前发展。 深圳北芯生命科技股份有限公司(以下简称"北芯生命")自2015年成立以来，始终专注于心血管疾病精准 诊疗创新医疗器械的研发、生产与销售。秉持"用创新和品质改善生命健康"的使命，北芯生命在该领域 不断深耕，取得了一系列成果。 历经九年多的研发创新，北芯生命逐步打破海外巨头在心血管精准介入领域的垄断局面，填补多项国产 空白。其境内外已获批十余张三类医疗器械注册证。截至2025 年 6 月 30 日，公司拥有 185 项境内外授 权专利，其中发明专利 86 项。 北芯生命自主研发的血管内超声(IVUS)系统为中国首个获批的国产高清(60 MHz) ...